Answers for Chronic Ocular Surface Pain (COSP) Clinical Trials

At Ophthalmic Trials Australia we have some great clinical trials for Chronic Ocular Surface Pain.

Here are the five latest clinical trials for chronic ocular surface pain:

  1. SAF312 Eye Drops for Post-operative Corneal Pain: This study evaluates the efficacy and safety of SAF312 eye drops in subjects with chronic post-operative corneal pain. The trial uses various outcome measures including changes in pain severity and frequency, as well as quality of life impacts assessed through the Ocular Pain Assessment Survey (OPAS). The study’s primary aim is to reduce pain severity as measured by the Visual Analog Scale (VAS)​ (Home – ClinicalTrials.gov)​.
  2. ETX-4143 Pilot Study: The Eyecool study is an adaptive, early-feasibility, open-label pilot trial investigating the effects of ETX-4143, a cooling mixture applied to the ocular surface to reduce pain receptor sensitivity. This trial is the first human study for ETX-4143, which has shown promising results in preclinical animal studies. Participants receive varying durations of treatment to assess efficacy and safety over eight weeks​ (Ophthalmic Trials Australia)​.
  3. SYL1001 Dose-finding Study: This phase 2 clinical trial explores the safety and effectiveness of different doses of SYL1001 eye drops in treating ocular pain associated with dry eye syndrome. The study compares SYL1001 with a placebo over ten days, with primary outcome measures including changes in pain levels and ocular discomfort as assessed by the Ocular Surface Disease Index (OSDI)​ (Home – ClinicalTrials.gov)​.
  4. Neurosensory Abnormalities in Ocular Surface Pain (NASA): This study aims to establish the prevalence of neuropathic corneal pain (NCP) and its overlap with dry eye disease (DED). Using a series of questionnaires and diagnostic tests, including the hyperosmolar response and proparacaine challenge tests, the trial assesses symptoms and quality of life impacts in patients with ocular surface discomfort. The study also seeks to classify subtypes of patients with neuropathic pain components​ (Home – ClinicalTrials.gov)​.
  5. Study of Efficacy and Safety of Latanoprostene Bunod for Ocular Surface Pain: This trial investigates the use of Latanoprostene Bunod, a prostaglandin analog, in managing chronic ocular surface pain. Participants are evaluated for changes in pain severity, ocular surface parameters, and overall comfort. The study aims to provide an alternative therapeutic approach for patients with chronic pain related to ocular surface diseases​ (Home – ClinicalTrials.gov)​.

These trials represent significant steps forward in understanding and managing chronic ocular surface pain, offering potential new therapies and insights into the mechanisms underlying this challenging condition.

Leave a comment

Your email address will not be published. Required fields are marked *